Newron Pharmaceuticals SpA (NWRN.SW) WACC Analysis

As of June 2, 2025, Newron Pharmaceuticals SpA (NWRN.SW) carries a Weighted Average Cost of Capital (WACC) of 7.0%. WACC reflects the blended rate Newron Pharmaceuticals SpA must pay to both equity and debt holders.

Within that, the cost of equity is 5.4%, the cost of debt is 4.0%, and the effective tax rate is 0.1%.

Breakdown of WACC Components

• Long-term bond rate: 1.0% – 1.5%
• Equity market risk premium: 5.1% – 6.1%
• Adjusted beta: 0.88 – 1.39
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 0.32

What It Means for Investors

With a selected WACC of 7.0%, Newron Pharmaceuticals SpA must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects an attractive low cost of capital.